Related by context. All words. (Click for frequent words.) 73 CI #.#-#.# [002] 72 % CI #.#-#.# [001] 68 P ≤ 68 % CI #.#-#.# [008] 66 CI -#.# 66 % Confidence Interval 66 CI #.#-#.# [001] 66 #.#-#.# p = 65 confidence interval CI 65 p = #.# [003] 65 confidence interval #.#-#.# 64 p ≤ 64 % CI #.#-#.# [007] 63 % CI #.#-#.# [003] 63 p = .# [002] 63 mmHg p = 62 -#.# ± [002] 62 Hazard Ratio HR 62 P = .# 62 mg p = 62 placebo Hazard Ratio 62 % CI #.#-#.# [005] 61 % CI #.#-#.# [002] 61 % CI #.#-#.# [006] 61 FOLFIRI alone 61 multivariable adjusted 61 BMS p = 61 Hazard Ratio = 61 statistically significant p = 60 CI = 60 NMIBC 60 TAXUS p value 60 % CI #.#-#.# [004] 60 AUC0 60 confidence intervals CIs 59 tirofiban 59 mmHg diastolic 59 Document Maker 59 ALT elevation 59 = #.#-#.# 59 pT3 59 r2 = 59 Hazard Ratio 59 #.#/#.# mmHg [001] 58 CRp 58 biochemical relapse 58 ug kg 58 PSA nadir 58 radiotherapy RT 58 Median PFS 58 progression TTP 57 p = NS 57 p = 57 HbA 1c levels 57 pmol L 57 conjugated equine estrogens 57 certolizumab 57 TURBT 57 creatinine ratio 57 tolterodine ER 57 5-FU/LV 57 NNT = 57 statistical significance p 57 nmol liter 57 preoperative PSA 57 lumbar spine BMD 57 Critical HR Recordkeeping 57 Partial Response 57 p = #.# [004] 57 interquartile range 57 adefovir treated 57 hip BMD 57 leukocyte count 57 PCWP 57 QTcF 57 noninferior 57 adjunctive placebo 57 pg mL 56 postoperative complication 56 x ULN 56 #OHD 56 placebo p = 56 CI -#.# -#.# 56 mL/min/#.# m 2 56 5 Fluorouracil 56 FOLFOX4 56 univariate analysis 56 rho = 56 nicardipine 56 MADRS score 56 morphometric vertebral fractures 56 -#.# mg dL [001] 56 epoetin alpha 56 μg d 56 -#.# log# 56 log# copies mL 56 log# IU mL 56 achieved statistical significance 56 CR CRu 56 generalized edema 56 deep venous thromboses 56 Zometa hazard 56 Xalatan R 56 cisplatin vinorelbine 56 IOP lowering 56 -#.# p = 55 HbA1C levels 55 tipranavir r 55 rh 55 μg kg 55 #mg BID [001] 55 corticosteroid dose 55 anastomotic leak 55 PEG IFN 55 Operative mortality 55 hepatorenal syndrome 55 -#.# USD JPY [002] 55 χ 55 nmol 55 multivariate adjusted 55 urine albumin 55 imiquimod cream 55 Secondary endpoints included 55 Kaplan Meier analysis 55 ritonavir boosted 55 methotrexate monotherapy 55 achieved ACR# 55 annualized relapse 55 binary restenosis 55 4mg/kg 55 interobserver reliability 55 Papillary 55 atherosclerotic renal artery stenosis 55 mIU ml 55 SB .# OBP 55 μg liter 55 biopsy Gleason 55 ARB telmisartan 55 Visual Analogue Scale VAS 55 posttransplant 55 uM 55 HR 55 chemoradiation therapy 55 #mg QD [001] 55 adenoma recurrence 55 oxycodone CR 55 pg ml 55 postop 55 mg qd 55 albumin excretion rate 55 cytoreductive nephrectomy 55 ischemia driven 55 histologic subtype 55 underwent resection 55 â ‰ ¥ 55 mU liter 55 Injury Severity Score 55 rFSH 55 adriamycin 55 infliximab monotherapy 54 clodronate 54 PaO 2 54 bronchioloalveolar carcinoma 54 WOMAC pain 54 labetalol 54 β = 54 oral allopurinol 54 posttreatment 54 kappa = 54 creatine kinase MB 54 logMAR 54 #.#,#.# [002] 54 mg/m2/day 54 nonsignificant difference 54 Etf Un TSX 54 #.#-#.# [002] 54 multivariate Cox 54 tipranavir ritonavir 54 mitoxantrone plus 54 neutrophil count 54 antiretroviral naïve 54 comparator arm 54 postprocedure 54 periprocedural 54 Patients Receiving 54 CR nPR 54 baseline FEV 54 #.#/#.# mm Hg [003] 54 ‰ ¥ 54 ATV RTV 54 neutrophil counts 54 Serum creatinine 54 min -1 54 docetaxel pretreated 54 ß blockers 54 Vancocin p = 54 fludarabine cyclophosphamide 54 preoperative chemotherapy 54 AOR = 54 achieved CCyR 54 TPV r 54 overt nephropathy 54 nonvertebral fractures 54 abdominal pain abdominal discomfort 54 PRADAXA #mg 54 recurrent venous thromboembolism 54 FOLPI 54 receiving VICTRELIS 54 baseline LDH 54 nonfatal MI 54 lymphocyte count 54 linaclotide treated 54 Retreatment 54 FOLFIRI 54 Key secondary endpoints 54 Kaplan Meier estimates 54 euthyroid 54 fluticasone salmeterol 54 ug ml 54 aortic root replacement 54 eptifibatide 54 conjugated estrogens 54 invasive carcinomas 54 pretest probability 54 hemoglobin A1c levels 54 regression coefficient 54 Doxil ® 54 SBP DBP 54 papillary thyroid carcinoma 54 -#.# mmol L 54 aOR 54 ertapenem 54 symptomatic intracranial hemorrhage 54 bivalirudin monotherapy 54 atazanavir ritonavir 54 piperacillin tazobactam 54 bioavailable testosterone 54 = .# 54 LV dysfunction 54 lowest tertile 54 AUCs 54 postmenopausal osteoporotic women 54 elevated transaminases 54 ASCUS 54 mol L 54 -#.# mm Hg 54 HOMA IR 54 gadolinium enhancing 54 lymphocytosis 54 nondiabetic patients 54 plus dexamethasone 54 progesterone receptor negative 54 glulisine 53 Ishak fibrosis score 53 biochemical recurrence 53 CDAI score 53 stent binary restenosis 53 PSQI 53 metastatic malignant 53 treat NNT 53 ug dose 53 baseline HbA1c 53 elevated LDH 53 postintervention 53 BENICAR HCT 53 serum magnesium 53 CCyR 53 Stent p = 53 thyroglobulin 53 femoral neck BMD 53 noncardiac 53 adjunctive ABILIFY 53 median PFS 53 mg BID dose 53 bronchoalveolar lavage 53 BENICAR 53 mmol kg 53 ATACAND 53 #-# Full Text 53 severe neutropenia 53 MBq 53 p = ns 53 DES implantation 53 severe exacerbations 53 Folfox 53 pretreatment serum 53 PASI scores 53 HBeAg seroconversion 53 extracapsular extension 53 treatment naive genotype 53 QD dosing 53 Partial Responses 53 intact parathyroid hormone 53 advanced adenoma 53 preintervention 53 liver histology 53 tPSA 53 pmol liter 53 esophagogastroduodenoscopy 53 T2 lesion volume 53 PSADT 53 mcg kg min 53 oral diclofenac 53 colorectal adenoma 53 ovarian carcinoma 53 #.#-#.# [005] 53 mU 53 pT2 53 platelet reactivity 53 μg mL 53 ß = 53 arterial thromboembolic events 53 SUVmax 53 #mg/m# [001] 53 #mg BID [003] 53 p = #.# [002] 53 of.# [001] 53 alanine aminotransferase ALT 53 -#.# ± [001] 53 lopinavir r arm 53 relapsed MM 53 budesonide pMDI 53 YEAR YEAR 53 Patency 53 advanced hepatocellular carcinoma 53 sUA 53 MACCE 53 EQ 5D 53 death reinfarction 53 Epirubicin 53 serum cortisol 53 troponin T 53 ml min 53 hemoglobin Hb 53 ECOG PS 53 Flu Cy 53 prespecified secondary 53 anemia hemoglobin 53 HBeAg negative patients 53 #mg QD [002] 53 -#.# mg dL [002] 53 QRS duration 53 mmol l 53 androgen suppression 53 CLL SLL 53 placebo p 53 nonsignificant 53 lymphadenectomy 53 dalteparin 53 detectable HCV RNA 53 IU ml 53 Yuan Keywords MARKETS 53 hc2 53 DAPT 53 octreotide LAR 53 Stent thrombosis 53 EBRT 53 debulking surgery 53 chlorambucil 53 tertile 53 completely resected 53 IQR 52 mean baseline A1C 52 efavirenz EFV 52 unfractionated heparin UFH 52 oxycodone IR 52 SHR VIEW 52 cGy 52 #.#-#.# [011] 52 #Gy 52 intima media thickness 52 serum aminotransferase levels 52 CIMZIA TM 52 lispro 52 nonvertebral fracture 52 prostatic adenocarcinoma 52 mg clopidogrel 52 drotrecogin alfa activated 52 microgram kg 52 leuprorelin 52 nonfasting triglyceride levels 52 mIU L 52 esophageal carcinoma 52 CI# [002] 52 seminal vesicle invasion 52 IFN alfa 52 FORINT HR HR 52 oblimersen 52 μmol L 52 postdischarge 52 total thyroidectomy 52 IFN α 52 amoxicillin clavulanate 52 prospectively stratified 52 nonobstructive 52 mg/m2 dose 52 Recap DET 52 NSTEMI 52 atorvastatin #mg 52 odds ratios ORs 52 echocardiographic parameters 52 moderate renal impairment 52 Immunohistochemical staining 52 mcg QD 52 mL sec 52 multivariable Cox 52 interquartile range IQR 52 thyroid carcinoma 52 Main Outcome Measure 52 abacavir lamivudine 52 pegylated interferon alpha 2a 52 mg TID 52 ratio ICER 52 reactive hyperemia 52 statistically significant p 52 salmeterol fluticasone propionate 52 Free Survival PFS 52 antithrombotic therapy 52 malignant neoplasm 52 serum alkaline phosphatase 52 ultrasonographic 52 TRUS 52 BEXXAR Therapeutic Regimen 52 DAS# CRP 52 aspartate aminotransferase AST 52 IIIa inhibitor 52 cyclophosphamide methotrexate 52 Postoperative 52 CORE OM 52 TIMP 1 52 HbA 1c 52 transabdominal 52 preterm neonates 52 biliary tract cancer 52 T1a 52 noncardiovascular mortality 52 CDAI 52 Secondary endpoints include 52 FluCAM arm 52 Hb A1C 52 pegylated interferon alfa 2b 52 univariate analyzes 52 nitroprusside 52 postinjury 52 reinfarction 52 tapentadol ER 52 g dl 52 cilostazol 52 SCr 52 gemcitabine cisplatin 52 noninferiority 52 statistical significance p = 52 perioperatively 52 anagrelide 52 plasma cortisol 52 multivariable analysis 52 Elitek 52 dose atorvastatin 52 placebo fluoxetine 52 CRu 52 Rate ORR 52 FluCAM 52 fluticasone propionate FP 52 endometrial thickness 52 Am J Cardiol 52 Crohn Disease Activity 52 ribavirin RBV 52 ACE Inhibitor 52 EuroSCORE 52 SVR# 52 μg L 52 interstitial brachytherapy 52 #.#ng/ml 52 ACUTE 52 inhospital mortality 52 serum TSH 52 abciximab 52 AST ALT 52 mEq L 52 racemic albuterol 52 histological subtype 52 proximal DVT 52 RECIST criteria 51 receiving ISENTRESS 51 mutated K ras 51 LV ejection fraction 51 β blockers 51 erythrocyte sedimentation rate 51 fluoropyrimidine 51 glucocorticoid induced 51 Negative Symptoms 51 cTnI 51 autologous SCT 51 LS BMD 51 Recap NYY 51 response CCyR 51 estimated glomerular filtration 51 DAS# remission 51 peg interferon 51 XIENCE V PROMUS Stent 51 IIIa inhibitors 51 FDG uptake 51 Index CDAI 51 ropivacaine 51 p = .# [001] 51 hepatic insulin sensitivity 51 HF hospitalization 51 mL/min/#.# m2 51 titrated glipizide 51 ARCOXIA 51 prospectively defined 51 Y BOCS 51 Secondary efficacy endpoints 51 invasive ductal 51 Thal Dex 51 mesilate 51 experienced virologic failure 51 adnexal mass 51 locoregional recurrence 51 mg kg Hematide 51 daunorubicin 51 arterial oxygen saturation 51 recurrent DVT 51 adverse cytogenetics 51 Castration Resistant Prostate Cancer 51 NIHSS score 51 J Hepatol 51 HbA1C 51 graft occlusion 51 SLNB 51 mg kg hr 51 EORTC QLQ C# 51 FSanchez Pittsburgh 51 CR coils 51 idraparinux 51 cystoid macular edema 51 endoscopic remission 51 vincristine doxorubicin 51 Lumbar spine 51 Postoperatively 51 univariate 51 hemodynamic measurements 51 nonfatal myocardial infarction 51 tumor progression TTP 51 glomerular filtration 51 prednisone prednisolone plus 51 left ventricular diastolic 51 CK # plasma concentrations 51 Decompensated Heart Failure 51 Recap TOR 51 primary patency 51 CsA 51 Kaplan Meier 51 HAQ DI 51 PANSS scores 51 J Clin 51 renal biopsy 51 Diastolic 51 mH 51 mean ± SEM 51 mcg albinterferon alfa 2b 51 Brief Psychiatric 51 Arch Intern Med 51 affective psychosis 51 nadolol 51 advanced adenomas 51 F FDG PET 51 mmol L. 51 prostate carcinoma 51 specific alkaline phosphatase 51 refractory NSCLC 51 intraclass correlation coefficient 51 biologic DMARD 51 postoperative mortality 51 HLA DR4 51 Pharmacokinetics PK 51 #.#/#.# mm Hg [001] 51 lactate dehydrogenase 51 NYHA functional class 51 tHcy 51 ULORIC 51 mesalamine granules 51 hormone receptor negative 51 distensibility 51 undergoing radical cystectomy 51 mEq 51 Peginterferon Alfa 2a 51 pulmonary exacerbation 51 simvastatin #mg 51 gemcitabine carboplatin 51 triiodothyronine 51 Adjuvant chemotherapy 51 interleukin IL -6 51 #mg #mg #mg [003] 51 Montgomery Åsberg Depression 51 XIENCE V vs. 51 CIMZIA ™ 51 TT genotype 51 Suppl. 51 immunostaining 51 RH Chad Gaudin 51 gm dl 51 rebleeding 51 mL kg 51 aldosterone antagonists 51 histologic findings 51 mcg mL 51 refractory ischemia 51 node metastases 51 atrioventricular block 51 alanine aminotransferase 51 CGuillén Detroit 51 mcg kg 51 mCi 51 #mg/day [002] 51 transdermal estradiol 51 Rating Scale BPRS 51 Recap NYM 51 mcg Albuferon 51 REYATAZ r arm 51 Endometrial 51 serum estradiol 51 colorectal carcinoma 51 haematologic 51 perioperative complications 51 galiximab 51 apolipoprotein B 51 cytologic 51 #/Aug 51 Hgb 51 Health Aff Millwood 51 mso footer margin 51 GG genotype 51 CIMZIA TM certolizumab pegol 51 pulmonary exacerbations 51 paraprotein 51 cerebral oxygenation 51 ACTEMRA TM 51 mg d 51 highest tertile 51 Suppl 51 XIENCE V demonstrated 51 Lucentis monotherapy 51 rizatriptan 50 placebo dexamethasone 50 cells mcL 50 Coronary Artery Bypass Graft 50 severe NCI Grades 50 angiographically 50 log# reduction 50 #r #h 50 acute cholecystitis 50 Median progression 50 SGRQ 50 eplerenone 50 Primary endpoints 50 J Natl Cancer Inst 50 Tumor Response 50 transvaginal sonography 50 EGFR mutation positive 50 interrater reliability 50 ng dL 50 CD4 CD8 50 CrCl 50 gastroduodenal 50 serum creatinine levels 50 ALSFRS R 50 FDA defined valvulopathy 50 g cm 50 lymph node metastasis 50 DAS# [002] 50 pCR 50 Live Equiv 50 Cronbach alpha 50 INVEGA ® 50 Ejection Fraction 50 DVFA SG 50 Cystatin C 50 Evaluable 50 corrected QT interval 50 mild renal insufficiency 50 mU L 50 atheroma volume 50 FOLFOX4 alone 50 interferon alfa 2a 50 superficial femoral 50 ZACTIMA 50 LPS induced 50 Adenomas 50 Annualized ROE 50 PREZISTA ritonavir 50 T2DM 50 left ventricular systolic 50 nonvertebral 50 lumen diameter 50 RGT arm 50 confirmed CCyR 50 mcg linaclotide 50 elevated troponin 50 RH Josh Beckett 50 nmol L 50 tumor regressions 50 PegIFN RBV 50 stage IIIb IV 50 ACR# ACR# 50 mg tid 50 neuropathy sensory 50 #.#mmol L [002] 50 adjuvant systemic 50 ® fluocinonide Cream 50 LDL triglycerides 50 serum HBV DNA 50 timepoints 50 cytogenetic abnormalities 50 mmHg systolic 50 pretransplant 50 adjuvant cisplatin 50 Skin sterol 50 NIH CPSI 50 TMC# r 50 Recap HOU 50 hepatic enzymes 50 diastolic velocity 50 localized renal 50 VGuerrero Los Angeles 50 revascularizations 50 See CLINICAL PHARMACOLOGY 50 plus medroxyprogesterone acetate 50 partial remissions 50 eg. Proved Producing 50 .# obp 50 sd = 50 diabetes mellitus DM 50 HAM D# scores 50 ± SEM 50 placebo PBO 50 aPTT 50 Taxus Stent 50 microg 50 radical prostatectomy RP 50 reteplase 50 neurodevelopmental impairment 50 CALGB # [002] 50 diameter stenosis 50 serum urate 50 CC genotype 50 nmol l 50 J Clin Oncol 50 Crit Care 50 plasma glucose concentration 50 HRCT 50 plus prednisone 50 doxorubicin cyclophosphamide 50 FOLFOX regimen 50 recurrent VTE 50 HGPIN 50 3mg/kg 50 lamivudine refractory patients 50 ACR# response 50 irbesartan 50 document.write unescape % 50 azilsartan medoxomil 50 CK MB 50 uL 50 creatinine clearance 50 EMRG VIO 50 ezetimibe simvastatin 50 Ann Intern Med 50 serum concentrations 50 symptomatic VTE 50 LVEF 50 Target Lesion Revascularization TLR 50 Relapsing Multiple Sclerosis 50 Pred Forte 50 ng dl 50 EDSS score 50 FOLFOX 50 intratumoral 50 intramuscularly 50 multivariable logistic regression 50 BEACOPP 50 histologically proven 50 pegylated IFN 50 RNA copies mL 50 suppl. 50 estimated GFR 50 CIN2 + 50 AUA Symptom Score 50 LPV r 50 CTEPH 50 HBeAg 50 Pegylated Liposomal Doxorubicin 50 non splenectomized 50 hematological parameters 50 kg -1 50 achieved PASI 50 sirolimus stent 50 CANADIAN DOLLAR JAPANESE YEN 50 Pemetrexed 50 hemoglobin A1c HbA1c 50 MCyR 50 SpO 2 50 0K 50 ng mL 50 Radical prostatectomy 50 alfa 2a 50 Prognostic significance 50 nadroparin 50 SGPT 50 extensive metabolizers 50 PREZISTA r arm 50 CABG p = 50 PCa 50 adenomatous 50 5q 50 QTc 50 IRLS score 50 microbiological eradication 50 Renal dysfunction 50 mitoxantrone 50 aspartate aminotransferase 50 recurrent ischemia 50 T1 hypointense lesions 50 Carotid Artery Stenting 50 postoperative AF 50 parous women 50 administered cetrorelix 50 RIGScan R 50 pegylated interferon alpha 50 glycated hemoglobin levels 50 Score TOS 50 darbepoetin alfa 50 mm Hg systolic 50 ejection fractions 50 DLQI 50 RARP 50 Apidra ® 50 CGuzman Washington 50 Natalizumab 50 needle aspiration 50 mcg BID 50 INRs 50 hemoptysis 50 nocturnal awakenings 50 Percutaneous Tibial Nerve Stimulation 50 vertebral fracture 50 leucopenia 50 mg ustekinumab 49 lamivudine monotherapy 49 HbA1c levels 49 adiponectin concentrations 49 Severity CGI S 49 transcranial Doppler ultrasound 49 gadolinium enhancing lesions 49 #.#mg/dL 49 antibody titer 49 spontaneous bacterial peritonitis 49 angiographic restenosis 49 tracheal intubation 49 obstructive CAD 49 mg QD 49 RENAL 49 prn 49 systolic BP 49 Free Full Text 49 RH Daisuke Matsuzaka 49 β blocker 49 neointimal 49 urate lowering therapy 49 GP IIb IIIa 49 bortezomib refractory 49 CZE Ducati #R #'# 49 oocytes retrieved 49 attain statistical significance 49 normotensive 49 periprocedural MI 49 achieved sustained virologic 49 Neurol 49 Bone Metastases 49 ANCOVA 49 Abstract P# [002] 49 pamidronate 49 detrusor overactivity 49 serum ALT 49 TRAIL R1 49 vasopressor 49 glycoprotein IIb IIIa inhibitors 49 serum albumin 49 acetazolamide 49 CODE § 49 mg Androxal 49 definite stent thrombosis 49 lactate dehydrogenase LDH 49 bivalirudin alone 49 Adefovir 49 Consensus +#.# 49 microvessel density 49 8mg/kg 49 complete cytogenetic response 49 #/#.# [008] 49 Demonstrate Significant 49 antiarrhythmic drug 49 VcMP 49 Angiographic 49 REMICADE monotherapy 49 Response Evaluation Criteria 49 Pelvic Organ Prolapse 49 Comorbidity 49 transthoracic echocardiography 49 TGZ 49 mitral annular 49 RECIST 49 rimonabant #mg 49 6MWD 49 RVOT 49 preoperatively 49 lopinavir r 49 tumor histology 49 liposome injection 49 ANN INTERN MED 49 sodium nitroprusside 49 microbiologically evaluable 49 μg ml 49 elevated ALT 49 secondary efficacy endpoint 49 serum biomarker 49 HDRS 49 nondiabetics 49 MOrdonez Detroit 49 ALT elevations 49 Stage IIIb 49 Supplemental Figure 49 Pain Intensity 49 Recap BAL 49 logistic regression analysis 49 Aplus.Net CNET EDITORS CHOICE 49 de novo AML 49 telaprevir dosed 49 hMG 49 2B 3B HR 49 transurethral 49 angiographic outcomes 49 urothelial carcinoma 49 carotid artery intima media 49 Schizophrenia Bulletin 49 Mg Uk 49 cystoscopic 49 -#.# log# copies mL 49 serum CRP 49 pericardial effusion 49 MIC# [001] 49 Double Blind Randomized 49 catheter colonization 49 monophasic 49 coronary stenosis 49 gastric adenocarcinoma 49 glutamyl 49 neutropaenia 49 thromboembolic events 49 UPDRS motor 49 sustained virological response 49 5FU 49 imipenem 49 YMRS 49 Eur Respir J 49 ischemic lesions 49 carotid intima media 49 NIHSS 49 free survival PFS 49 MSLT 49 MS DRGs 49 IsoP 49 Arch Neurol 49 PANSS total 49 HBeAg + 49 F FLT 49 T2 lesions 49 hypogonadal 49 SSosa 49 squamous intraepithelial lesions 49 invasive lobular 49 SELENA SLEDAI 49 median CD4 49 % #lt ;/ 49 plasma creatinine 49 RBC transfusion 49 saline placebo 49 clinically meaningful improvement 49 hypomagnesemia 49 albumin excretion 49 Adjusted Margin 49 CDelgado Toronto 49 epididymal 49 KRAS mutant tumors 49 Pearson correlation coefficient 49 stent thromboses 49 YR BUND YLD 49 oxyhemoglobin 49 pegylated interferon alfa